{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:41Z","timestamp":1791925421855,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To assess the impact of long-acting insulin analogues, compared to intermediate acting neutral protamine Hagedron (NPH), on maternal, perinatal and neonatal outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Studies for inclusion in the review were identified using a structured search strategy in PubMed, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) database. Studies that were randomized controlled trials or observational in design were considered for inclusion. Eligible studies should have compared the maternal, perinatal and neonatal outcomes between pregnant women with gestational diabetes mellitus (GDM) managed by intermediate acting (NPH) and by long-acting insulin analogues. Statistical analysis was performed using STATA software.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found 17 studies to be eligible for inclusion. The mean gestational weight gain and risk of maternal hypoglycaemia, hypertensive disorder, caesarean delivery, spontaneous abortion, endometritis and wound infection or dehiscence were similar among pregnant women with GDM managed using long-acting insulin analogues and NPH. Those receiving long-acting insulin analogues had significantly lower HbA1c values in the second (WMD \u2212\u00a0.09, 95% CI 0.12, \u2212\u00a00.06; N\u2009=\u20094) and third trimester (WMD \u2212\u00a00.08, 95% CI \u2212\u00a00.14, \u2212\u00a00.02; N\u2009=\u200912). The mean gestational age and birth weight and risk of perinatal mortality, prematurity, large for gestational age, small for gestational age, shoulder dystocia and congenital abnormalities was similar among babies in both groups. No statistically significant differences in risk of admission to neonatal intensive care unit, respiratory distress, neonatal hypoglycaemia, 5\u00a0min APGAR score of\u2009&lt;\u20097, neonatal hyperbilirubinemia and sepsis was observed. The quality of pooled evidence, as per GRADE criteria, was judged to be \u201cvery low\u201d for all the maternal and neonatal outcomes considered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Findings suggest no significant differences in the maternal, perinatal and neonatal outcomes between intermediate and long-acting insulin analogues. The results provide support for use of long-acting insulin analogues in women with GDM. However, evidence is still needed from high quality randomized controlled trials to arrive at a recommendation for inclusion in routine clinical care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13098-022-00925-7","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T05:02:58Z","timestamp":1666328578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Maternal and neonatal outcomes with the use of long acting, compared to intermediate acting basal insulin (NPH) for managing diabetes during pregnancy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Jijiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"2","key":"925_CR1","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.2337\/dc07-s206","volume":"30","author":"A Ferrara","year":"2007","unstructured":"Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care. 2007;30(2):S141-146.","journal-title":"Diabetes Care"},{"key":"925_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11892-015-0699-x","volume":"16","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diab Rep. 2016;16:7.","journal-title":"Curr Diab Rep"},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.3390\/ijms19113342","volume":"19","author":"JF Plows","year":"2018","unstructured":"Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19:3342.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"925_CR4","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.2337\/dc07-s202","volume":"30","author":"LA Barbour","year":"2007","unstructured":"Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30(2):S112-119.","journal-title":"Diabetes Care"},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1210\/jc.2006-0624","volume":"91","author":"L-S Fetita","year":"2006","unstructured":"Fetita L-S, Sobngwi E, Serradas P, Calvo F, Gautier J-F. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab. 2006;91:3718\u201324.","journal-title":"J Clin Endocrinol Metab"},{"key":"925_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ajog.2004.11.039","volume":"192","author":"O Langer","year":"2005","unstructured":"Langer O, Yogev Y, Most O, Xenakis EMJ. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol. 2005;192:989\u201397.","journal-title":"Am J Obstet Gynecol"},{"key":"925_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.285","volume":"4","author":"SK Mistry","year":"2021","unstructured":"Mistry SK, Das Gupta R, Alam S, Kaur K, Shamim AA, Puthussery S. Gestational diabetes mellitus (GDM) and adverse pregnancy outcome in South Asia: a systematic review. Endocrinol Diabetes Metab. 2021;4: e00285.","journal-title":"Endocrinol Diabetes Metab"},{"key":"925_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2393-12-23","volume":"12","author":"EM Wendland","year":"2012","unstructured":"Wendland EM, Torloni MR, Falavigna M, Trujillo J, Dode MA, Campos MA, et al. Gestational diabetes and pregnancy outcomes\u2013a systematic review of the world health organization (WHO) and the international association of diabetes in pregnancy study groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth. 2012;12:23.","journal-title":"BMC Pregnancy Childbirth"},{"key":"925_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14767050801929430","volume":"21","author":"BR Vohr","year":"2008","unstructured":"Vohr BR, Boney CM. Gestational diabetes: the forerunner for the development of maternal and childhood obesity and metabolic syndrome? J Matern Fetal Neonatal Med. 2008;21:149\u201357.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"2","key":"925_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2337\/diab.34.2.S119","volume":"34","author":"DJ Petitt","year":"1985","unstructured":"Petitt DJ, Bennett PH, Knowler WC, Baird HR, Aleck KA. Gestational diabetes mellitus and impaired glucose tolerance during pregnancy. Long-term effects on obesity and glucose tolerance in the offspring. Diabetes. 1985;34(2):119\u201322.","journal-title":"Diabetes."},{"key":"925_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7326\/0003-4819-159-2-201307160-00661","volume":"159","author":"L Hartling","year":"2013","unstructured":"Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. preventive services task force and the national institutes of health office of medical applications of research. Ann Intern Med. 2013;159:123\u20139.","journal-title":"Ann Intern Med"},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.2337\/dc18-S013","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 13. management of diabetes in pregnancy: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S137-43.","journal-title":"Diabetes Care"},{"key":"925_CR13","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc18-S008","volume":"41","author":"AD Association","year":"2018","unstructured":"Association AD. 8 Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142018. Diabetes Care Am Diabet Assoc. 2018;41:S73-85.","journal-title":"Diabetes Care. Am Diabet Assoc"},{"key":"925_CR14","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.2337\/diabetes.49.12.2142","volume":"49","author":"M Lepore","year":"2000","unstructured":"Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142\u20138.","journal-title":"Diabetes"},{"key":"925_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2006.10.015","volume":"77","author":"SCL Gough","year":"2007","unstructured":"Gough SCL. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 2007;77:1\u201315.","journal-title":"Diabetes Res Clin Pract"},{"key":"925_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","volume":"23","author":"H Yki-J\u00e4rvinen","year":"2000","unstructured":"Yki-J\u00e4rvinen H, Dressler A, Ziemen M, HOE 901\/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901\/3002 study group. Diabetes Care. 2000;23:1130\u20136.","journal-title":"Diabetes Care."},{"key":"925_CR17","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/dom.12106","volume":"15","author":"BM Frier","year":"2013","unstructured":"Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab. 2013;15:978\u201386.","journal-title":"Diabetes Obes Metab"},{"key":"925_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/649070","volume":"2012","author":"J Lepercq","year":"2012","unstructured":"Lepercq J, Lin J, Hall GC, Wang E, Dain M-P, Riddle MC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int. 2012;2012: 649070.","journal-title":"Obstet Gynecol Int"},{"key":"925_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1345\/aph.1P327","volume":"45","author":"E Pollex","year":"2011","unstructured":"Pollex E, Moretti ME, Koren G, Feig DS. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother. 2011;45:9\u201316.","journal-title":"Ann Pharmacother"},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00404-015-3692-3","volume":"292","author":"S Lv","year":"2015","unstructured":"Lv S, Wang J, Xu Y. Safety of insulin analogs during pregnancy: a meta-analysis. Arch Gynecol Obstet. 2015;292:749\u201356.","journal-title":"Arch Gynecol Obstet"},{"key":"925_CR21","unstructured":"PRISMA. http:\/\/www.prisma-statement.org\/PRISMAStatement\/. Accessed on Sep 11 2021."},{"key":"925_CR22","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. British Medical Journal Publishing Group; 2019; 366:l4898. https:\/\/www.bmj.com\/content\/366\/bmj.l4898. Accessed on Sep 3 2022.","DOI":"10.1136\/bmj.l4898"},{"key":"925_CR23","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"925_CR24","doi-asserted-by":"publisher","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods. 2021 12:55\u201361. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/jrsm.1411. Accessed on Sep 3 2022.","DOI":"10.1002\/jrsm.1411"},{"key":"925_CR25","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. https:\/\/handbook-5-1.cochrane.org\/. Accessed on 22 Aug 2021"},{"key":"925_CR26","doi-asserted-by":"crossref","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ [Internet]. British Medical Journal Publishing Group; 1997. 315:629\u201334. https:\/\/www.bmj.com\/content\/315\/7109\/629. Accessed on 16 Aug 2021.","DOI":"10.1136\/bmj.315.7109.629"},{"key":"925_CR27","unstructured":"McMaster University > CE&B Grade > GRADEpro. https:\/\/cebgrade.mcmaster.ca\/gradepro.html. Accessed on 3 Sep 2022."},{"key":"925_CR28","doi-asserted-by":"publisher","first-page":"87.e1","DOI":"10.1016\/j.ajog.2021.04.223","volume":"225","author":"M FishelBartal","year":"2021","unstructured":"FishelBartal M, Ward C, Blackwell SC, Ashby Cornthwaite JA, Zhang C, Refuerzo JS, et al. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial. Am J Obstet Gynecol. 2021;225:87.e1-87.e10.","journal-title":"Am J Obstet Gynecol"},{"key":"925_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejogrb.2016.07.490","volume":"206","author":"A Chico","year":"2016","unstructured":"Chico A, Herranz L, Corcoy R, Ram\u00edrez O, Goya MM, Bellart J, et al. Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. Eur J Obstet Gynecol Reprod Biol. 2016;206:84\u201391.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"925_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1055\/s-0039-1694733","volume":"37","author":"M FishelBartal","year":"2020","unstructured":"FishelBartal M, Ward C, Refuerzo JS, Ashimi SS, Joycelyn CA, Chen H-Y, et al. Basal insulin analogs versus neutral protamine Hagedorn for type 2 diabetics. Am J Perinatol. 2020;37:30\u20136.","journal-title":"Am J Perinatol"},{"issue":"426","key":"925_CR31","first-page":"e1","volume":"213","author":"KM Herrera","year":"2015","unstructured":"Herrera KM, Rosenn BM, Foroutan J, Bimson BE, Al Ibraheemi Z, Moshier EL, et al. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes. Am J Obstet Gynecol. 2015;213(426):e1-7.","journal-title":"Am J Obstet Gynecol"},{"key":"925_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/14767058.2013.799650","volume":"27","author":"M Hod","year":"2014","unstructured":"Hod M, Mathiesen ER, Jovanovi\u010d L, McCance DR, Ivanisevic M, Dur\u00e1n-Garcia S, et al. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med. 2014;27:7\u201313.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"925_CR33","doi-asserted-by":"publisher","first-page":"e001155","DOI":"10.1136\/bmjdrc-2019-001155","volume":"8","author":"J ji","year":"2020","unstructured":"ji J, He Z, Yang Z, Mi Y, Guo N, Zhao H, et al. Comparing the efficacy and safety of insulin detemir versus neutral protamine Hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study. BMJ Open Diabetes Res Care. 2020;8:e001155.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"925_CR34","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.2337\/dc11-2264","volume":"35","author":"ER Mathiesen","year":"2012","unstructured":"Mathiesen ER, Hod M, Ivanisevic M, Duran Garcia S, Br\u00f8ndsted L, Jovanovic L, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35:2012\u20137.","journal-title":"Diabetes Care"},{"key":"925_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/1060028019897897","volume":"54","author":"A Sleeman","year":"2020","unstructured":"Sleeman A, Odom J, Schellinger M. Comparison of hypoglycemia and safety outcomes with long-acting insulins versus insulin NPH in pregestational and gestational diabetes. Ann Pharmacother. 2020;54:669\u201375.","journal-title":"Ann Pharmacother"},{"key":"925_CR36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1464-5491.2008.02485.x","volume":"25","author":"G Di Cianni","year":"2008","unstructured":"Di Cianni G, Torlone E, Lencioni C, Bonomo M, Di Benedetto A, Napoli A, et al. Perinatal outcomes associated with the use of glargine during pregnancy. Diabet Med. 2008;25:993\u20136.","journal-title":"Diabet Med"},{"key":"925_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1055\/s-0029-1220782","volume":"26","author":"RS Egerman","year":"2009","unstructured":"Egerman RS, Ramsey RD, Kao LW, Bringman JJ, Haerian H, Kao JL, et al. Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol. 2009;26:591\u20135.","journal-title":"Am J Perinatol"},{"key":"925_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/14767050802638170","volume":"22","author":"YMV Fang","year":"2009","unstructured":"Fang YMV, MacKeen D, Egan JFX, Zelop CM. Insulin glargine compared with neutral protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med. 2009;22:249\u201353.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"925_CR39","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.clinthera.2008.08.013","volume":"30","author":"MP Imbergamo","year":"2008","unstructured":"Imbergamo MP, Amato MC, Sciortino G, Gambina M, Accidenti M, Criscimanna A, et al. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther. 2008;30:1476\u201384.","journal-title":"Clin Ther"},{"key":"925_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.diabres.2010.03.015","volume":"89","author":"CA Negrato","year":"2010","unstructured":"Negrato CA, Rafacho A, Negrato G, Teixeira MF, Ara\u00fajo CAR, Vieira L, et al. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract. 2010;89:46\u201351.","journal-title":"Diabetes Res Clin Pract"},{"key":"925_CR41","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/00016340701515282","volume":"86","author":"M P\u00f6yh\u00f6nen-Alho","year":"2007","unstructured":"P\u00f6yh\u00f6nen-Alho M, R\u00f6nnemaa T, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand. 2007;86:1171\u20134.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"925_CR42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1471-0528.2006.01216.x","volume":"114","author":"N Price","year":"2007","unstructured":"Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG. 2007;114:453\u20137.","journal-title":"BJOG"},{"key":"925_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-0028-1095181","volume":"26","author":"JG Smith","year":"2009","unstructured":"Smith JG, Manuck TA, White J, Merrill DC. Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy. Am J Perinatol. 2009;26:57\u201362.","journal-title":"Am J Perinatol"},{"key":"925_CR44","first-page":"491","volume":"34","author":"MP Imbergamo","year":"2012","unstructured":"Imbergamo MP, Amato MC, Amodeo R, Magistro A, Galluzzo A, Giordano C. Use of basal insulin analog detemir in pregnant women with type 1 diabetes: a case-control retrospective study. Giornale italiano di ostetricia e ginecologia. CIC Edizioni internazionali. 2012;34:491\u20138.","journal-title":"CIC Edizioni internazionali"},{"key":"925_CR45","doi-asserted-by":"crossref","unstructured":"Bugazia S, Boshnaf M, Elbahnasawy M, Shehata M, Alqatati F, Ragab KM, et al. Neonatal and Maternal Outcomes of Insulin Detemir versus Neutral Protamine Hagedorn for Diabetes Mellitus in Pregnancy. Current Women`s Health Reviews. 19:1\u20131. https:\/\/www.eurekaselect.com\/article\/124661. Accessed on 3 Sep 2022.","DOI":"10.2174\/1573404819666220621092340"},{"key":"925_CR46","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","volume":"49","author":"P Kurtzhals","year":"2000","unstructured":"Kurtzhals P, Sch\u00e4ffer L, S\u00f8rensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999\u20131005.","journal-title":"Diabetes"},{"key":"925_CR47","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00125-010-1760-6","volume":"53","author":"L Sciacca","year":"2010","unstructured":"Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010;53:1743\u201353.","journal-title":"Diabetologia"},{"key":"925_CR48","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1210\/jcem.86.12.8110","volume":"86","author":"TP Ciaraldi","year":"2001","unstructured":"Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab. 2001;86:5838\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"925_CR49","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1007\/s00125-005-1874-4","volume":"48","author":"K Staiger","year":"2005","unstructured":"Staiger K, Staiger H, Schweitzer MA, Metzinger E, Balletshofer B, H\u00e4ring H-U, et al. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia. 2005;48:1898\u2013905.","journal-title":"Diabetologia"},{"key":"925_CR50","first-page":"34","volume":"60","author":"K Ze\u0142obowska","year":"2009","unstructured":"Ze\u0142obowska K, Gumprecht J, Grzeszczak W. Mitogenic potency of insulin glargine. Endokrynol Pol. 2009;60:34\u20139.","journal-title":"Endokrynol Pol"},{"key":"925_CR51","doi-asserted-by":"publisher","first-page":"e9540","DOI":"10.1371\/journal.pone.0009540","volume":"5","author":"MR Sommerfeld","year":"2010","unstructured":"Sommerfeld MR, M\u00fcller G, Tschank G, Seipke G, Habermann P, Kurrle R, et al. In Vitro Metabolic and Mitogenic signaling of insulin glargine and its metabolites. PLOS ONE Public Library of Science. 2010;5:e9540.","journal-title":"PLOS ONE Public Library of Science"},{"key":"925_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2337\/dc09-1045","volume":"33","author":"EK Pollex","year":"2010","unstructured":"Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care. 2010;33:29\u201333.","journal-title":"Diabetes Care"},{"key":"925_CR53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.dsx.2021.01.012","volume":"15","author":"P Jethwani","year":"2021","unstructured":"Jethwani P, Saboo B, Jethwani L, Chawla R, Maheshwari A, Agarwal S, et al. Use of insulin glargine during pregnancy: a review. Diabetes Metab Syndr. 2021;15:379\u201384.","journal-title":"Diabetes Metab Syndr"},{"key":"925_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12884-019-2249-z","volume":"19","author":"L Liu","year":"2019","unstructured":"Liu L, Ma Y, Wang N, Lin W, Liu Y, Wen D. Maternal body mass index and risk of neonatal adverse outcomes in China: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2019;19:105.","journal-title":"BMC Pregnancy Childbirth"},{"key":"925_CR55","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/ajo.12866","volume":"59","author":"Z Yang","year":"2019","unstructured":"Yang Z, Phung H, Freebairn L, Sexton R, Raulli A, Kelly P. Contribution of maternal overweight and obesity to the occurrence of adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol. 2019;59:367\u201374.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"925_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12939-017-0715-7","volume":"17","author":"MK Kim","year":"2018","unstructured":"Kim MK, Lee SM, Bae S-H, Kim HJ, Lim NG, Yoon S-J, et al. Socioeconomic status can affect pregnancy outcomes and complications, even with a universal healthcare system. International Journal for Equity in Health. 2018;17:2.","journal-title":"International Journal for Equity in Health"},{"key":"925_CR57","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1097\/HJH.0b013e3282fcc36e","volume":"26","author":"LM Silva","year":"2008","unstructured":"Silva LM, Coolman M, Steegers EA, Jaddoe VW, Moll HA, Hofman A, et al. Low socioeconomic status is a risk factor for preeclampsia: the generation R Study. J Hypertens. 2008;26:1200\u20138.","journal-title":"J Hypertens"},{"key":"925_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12884-017-1418-1","volume":"17","author":"A Cantarutti","year":"2017","unstructured":"Cantarutti A, Franchi M, MonzioCompagnoni M, Merlino L, Corrao G. Mother\u2019s education and the risk of several neonatal outcomes: an evidence from an Italian population-based study. BMC Pregnancy Childbirth. 2017;17:221.","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-022-00925-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-022-00925-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-022-00925-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T07:12:30Z","timestamp":1666422750000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-022-00925-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1186\/s13098-022-00925-7","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}